PODXL and esophageal adenocarcinoma: This is in contrast to our previous findings [29] of PODXL being an independent prognostic biomarker for poor survival in gastric and esophageal adenocarcinoma treated with surgery up-front, thus suggesting a possible predictive role for PODXL.